Dose escalation of a curcuminoid formulation

Christopher D. Lao, Mack T. Ruffin IV, Daniel Normolle, Dennis D. Heath, Sandra I. Murray, Joanne M. Bailey, Martha E. Boggs, James Crowell, Cheryl L. Rock, Dean E. Brenner

Research output: Contribution to journalArticle

689 Citations (Scopus)

Abstract

Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™ Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 Mg. Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg. Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.

Original languageEnglish (US)
Article number10
JournalBMC complementary and alternative medicine
Volume6
DOIs
StatePublished - Mar 17 2006

Fingerprint

Curcumin
Curcuma
Spices
Southeastern Asia
Maximum Tolerated Dose
Chemoprevention
Powders
Toxicology
Biological Availability
India
Colorectal Neoplasms
Healthy Volunteers
Pharmacology
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

Lao, C. D., Ruffin IV, M. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., ... Brenner, D. E. (2006). Dose escalation of a curcuminoid formulation. BMC complementary and alternative medicine, 6, [10]. https://doi.org/10.1186/1472-6882-6-10
Lao, Christopher D. ; Ruffin IV, Mack T. ; Normolle, Daniel ; Heath, Dennis D. ; Murray, Sandra I. ; Bailey, Joanne M. ; Boggs, Martha E. ; Crowell, James ; Rock, Cheryl L. ; Brenner, Dean E. / Dose escalation of a curcuminoid formulation. In: BMC complementary and alternative medicine. 2006 ; Vol. 6.
@article{b69f330c74d24aac991322fe411f97d9,
title = "Dose escalation of a curcuminoid formulation",
abstract = "Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™ Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 Mg. Results: Seven of twenty-four subjects (30{\%}) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg. Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.",
author = "Lao, {Christopher D.} and {Ruffin IV}, {Mack T.} and Daniel Normolle and Heath, {Dennis D.} and Murray, {Sandra I.} and Bailey, {Joanne M.} and Boggs, {Martha E.} and James Crowell and Rock, {Cheryl L.} and Brenner, {Dean E.}",
year = "2006",
month = "3",
day = "17",
doi = "10.1186/1472-6882-6-10",
language = "English (US)",
volume = "6",
journal = "BMC Complementary and Alternative Medicine",
issn = "1472-6882",
publisher = "BioMed Central",

}

Lao, CD, Ruffin IV, MT, Normolle, D, Heath, DD, Murray, SI, Bailey, JM, Boggs, ME, Crowell, J, Rock, CL & Brenner, DE 2006, 'Dose escalation of a curcuminoid formulation', BMC complementary and alternative medicine, vol. 6, 10. https://doi.org/10.1186/1472-6882-6-10

Dose escalation of a curcuminoid formulation. / Lao, Christopher D.; Ruffin IV, Mack T.; Normolle, Daniel; Heath, Dennis D.; Murray, Sandra I.; Bailey, Joanne M.; Boggs, Martha E.; Crowell, James; Rock, Cheryl L.; Brenner, Dean E.

In: BMC complementary and alternative medicine, Vol. 6, 10, 17.03.2006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose escalation of a curcuminoid formulation

AU - Lao, Christopher D.

AU - Ruffin IV, Mack T.

AU - Normolle, Daniel

AU - Heath, Dennis D.

AU - Murray, Sandra I.

AU - Bailey, Joanne M.

AU - Boggs, Martha E.

AU - Crowell, James

AU - Rock, Cheryl L.

AU - Brenner, Dean E.

PY - 2006/3/17

Y1 - 2006/3/17

N2 - Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™ Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 Mg. Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg. Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.

AB - Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™ Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 Mg. Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg. Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.

UR - http://www.scopus.com/inward/record.url?scp=33645648062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645648062&partnerID=8YFLogxK

U2 - 10.1186/1472-6882-6-10

DO - 10.1186/1472-6882-6-10

M3 - Article

C2 - 16545122

AN - SCOPUS:33645648062

VL - 6

JO - BMC Complementary and Alternative Medicine

JF - BMC Complementary and Alternative Medicine

SN - 1472-6882

M1 - 10

ER -